SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
AMGN Analysis & Videos »
AMGN: Bull or Bear?
FDA Calendar Updates: EURX, AMGN, FOLD, ONTY, MEDX
AMGN
|
|
|
+0.94%
in
12 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-st...
|
New Index of Highly Defensive Market Cap Leaders
AMGN
|
|
|
-9.19%
in
117 days
(closed on 06/22/09)
The ETF Innovators Highly Defensive Index contains 40 market cap leading companies which are based in either North America or Europe from the defensive industry groups (A-K) specified below. www.BioMedReports.com - Mike Havrilla (A) Mass Merchant Discount Retailer (1): Wal-Mart (WMT) <> <> (B) Consumer Staples (12): Coca-Cola (KO), Colgate-Palmolive (CL), Diageo (DEO), General Mills (GIS), Danone (GDNNY), Kraft Foods (KFT), Nestle (NSRGY), PepsiCo (PEP), Philip Morris International (PM), Procter & Gamble (PG), Reckitt Benckiser (RBGPF), Unilever (UN) <><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< />...
|
Bullish on AMGN ...
AMGN
|
|
|
+0.00%
in
1 minute
(closed on 02/25/09)
New Index of Highly Defensive Market Cap Leaders The ETF Innovators Highly Defensive Index contains 40 market cap leading companies which are based in either North America or Europe from the defensive industry groups (A-K) specified below. www.BioMedReports.com - Mike Havrilla (A) Mass Merchant Discount Retailer (1): Wal-Mart (WMT) <> <> (B) Consumer Staples (12): Coca-Cola (KO), Colgate-Palmolive (CL), Diageo (DEO), General Mills (GIS), Danone (GDNNY), Kraft Foods (KFT), Nestle (NSRGY), PepsiCo (PEP), Philip Morris International (PM), Pro<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>< />...
|
Create Your Own Highly Defensive ETF
AMGN
|
|
|
+2.58%
in
35 days
(closed on 02/25/09)
Create Your Own Highly Defensive ETF The table at my website link below contains 35 companies included in the ETF Innovators [ETFI] Highly Defensive PerformIdex which are based in the U.S., Canada, and Europe with market caps over $10B that are the leaders by market cap in their defensive industry groups. The index includes 23 consumer staples and healthcare companies, with the remaining 12 companies chosen from a variety of other defensive industry groups. <> (A) Mass Merchant Dis...
|
A New Index of Health Product Innovators
AMGN
|
|
|
-7.57%
in
16 days
(closed on 01/21/09)
<> 
The accompanying table includes statistics and all 23 companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the past 12 months for an original new drug product or medical device.
The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding all new formulations of existing drugs, generic drugs, and label extensions for existing products). Also, companies whi...
|
Four Healthy Stocks Trading Above Moving Averages
AMGN
|
|
|
+2.65%
in
4 days
(closed on 01/05/09)
Amgen (AMGN), AspenBio Pharma (APPY), BioDelivery Sciences (BDSI), and Cypress Bioscience (CYPB) are four healthcare stocks that I follow which are poised to close out a rough 2008 for the overall market trading above their 50 and 200-day moving averages, in addition to having significant catalysts in 2009 which may lead to further gains. Below is a summary of the 2009 catalysts for these companies and click on the names or tickers below for a link to all of the articles on my blog for each stock: <> Amgen filed a BLA for bone drug denosumab in the following two indicatio...
|
A New Index of Highly Defensive Stocks
AMGN
|
|
|
+0.58%
in
2 days
(closed on 12/31/08)
<> The table at my website link below includes an update for the ETF Innovators [ETFI] Highly Defensive PerformIdex of 36 companies based in the <st1:country-region> <st1:place> U.S. </st1:place> </st1:country-region> , <st1:country-region> <st1:place> Canada </st1:place> </st1:country-region> , and <st1:place> Europe </st1:place> with market caps over $10B, which are the leaders by market cap in their defensive industry groups. The 36 companies are dominated by consumer staples and healthcare, with an equal distribution of 12 each from these sectors, with the remaining 12 compan...
|
FDA Calendar: High Hopes for Amgen's Bone Drug
AMGN
|
|
|
-1.39%
in
9 days
(closed on 12/29/08)
<> 
The accompanying table [click to enlarge] includes an updated FDA calendar of 69 expected decision dates included in the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, with seven companies listed in red with overdue decisions. Since my last update , the following FDA action has occurred:
1.) Amgen (AMGN) filed a BLA for bone drug denosumab in the following two indications: the treatment + prevention of osteoporosis in post-menopausal women and the treatment + prevention of bone loss in patient...
|
R&D Leads to Higher Returns for Top 20 Health Innovators
AMGN
|
|
|
+4.55%
in
27 days
(closed on 12/20/08)
<> 
<> The accompanying table includes statistics and the top 20 rated companies in the ETF Innovators [ETFI] Global Health Innovators Index of companies with market caps over $250M which received FDA approval in the trailing 12-month period for either an original new drug product or medical device. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding reformulations of existing drugs, generic drugs, and label extensions for exist...
|
Stock Picks for a 'Roadhouse Blues' Market
AMGN
|
|
|
+6.88%
in
2 days
(closed on 11/23/08)
<> The fear and pessimism behind major selling pressure and stock market losses can be summarized by the late Jim Morrison in a song by The Doors called 'Roadhouse Blues' – "The future's uncertain, and the end is always near." Some stocks that I follow which are trading at less than half of the 20% decline for the S&P 500 ETF (SPY) below its 50-day moving average are highlighted below.
Earlier this week, AspenBio Pharma (APPY) reported that its key clinical trial was nearly 90% enrolled for AppyScore, which is a blood-...
|
Who Will Replace GM in the Dow?
AMGN
|
|
|
-10.58%
in
10 days
(closed on 11/21/08)
<> While the fate of General Motors (GM) as a company is being debated by legislators and others, investors would agree that GM will be removed from the Dow Jones Industrial Average as the common stock faces the likely prospect of heading to zero despite efforts for a bailout of workers and suppliers. Some companies to consider as a replacement for GMK include:
Abbott Labs (ABT) is a consistent performer with diversified healthcare operations included pharmaceuticals, diagnostics, medical nutrition products, and medical devices/stents...
|
My 60 Defensive Growth Stock Picks at Inner8.com
AMGN
|
|
|
+3.82%
in
17 days
(closed on 11/11/08)
<> 
<> The accompanying table presents my 60 defensive growth stock picks at the recently launched online investing site Inner8.com , which I wrote about yesterday. My picks are focused on healthcare and consumer staples, along with some cash rich tech companies such as Microsoft (MSFT). My picks include companies across the entire spectrum of market cap and risk in the biotech industry, ranging from top performers such as Amgen (AMGN) and Celgene (CELG) to small and micro-cap picks such as Discovery Labs (DSCO), ...
|
Amgen Exceeds Expectations, Again
AMGN
|
|
|
+12.84%
in
3 days
(closed on 10/25/08)
<> Shares of Amgen (AMGN) have moved into the green in after-hours trading following a late-day Wall Street sell-off that had the Dow tanking by over 500 points. As I wrote earlier today , Amgen was able to both exceed profit and sales expectations for 3Q08 and raise its full-year profit guidance as it had done three months ago when reporting 2Q08 results. Even with the current pop in after-hours to around $54 per share, Amgen is only trading at a PE of 12X on the mid-point of its 2008 profit guidance of $4.45 to $4.55 per share.Amgen poste...
|
An Earnings Encore for Amgen?
AMGN
|
|
|
-2.11%
in
5 hours
(closed on 10/22/08)
<> 
I think Amgen (AMGN) will beat consensus estimates for sales and profits again today when it reports after the market close, continuing the same trends as last quarter, including better than expected sales of embattled anemia drugs Aranesp and Epogen. Amgen reported 2Q08 results (see conference call transcript ) that beat consensus analyst estimates and raised its full-year [FY] guidance for earnings and revenue, thanks to much stronger-than-expected sales of its anemia drugs Aranesp and Epogen:
- 2Q08 Revenue +1% at $3.8 bi...
|
People Bullish on AMGN
People Bearish on AMGN
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on AMGN |
Portfolio results thru 8/8/08
- Portfolio at www.updown.com - started 1/11/08
9.8% return includes dividends and commission.
Started socialpicks on 6/30. some stocks here are not in...
|
Stock update and watch list 7/29/08
- Due to difficulties understanding the socialpicks system regarding changing rating from buy to hold and thus resetting the performance, I wanted to sum...
|
Take a Close Look at Amgen
- It was a relatively slow day for news coming out of the markets, and there is about as much coverage of Super Bowl commercials as anything else. Perhap...
|
More Resources
|
About Amgen Inc
- Answers.com
There were a few stocks in 2008 that exhibited great performance despite horrible market conditions. And these gems of 2008 may provide investors with a safe haven of sorts for 2009. 
